Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 plus Enasidenib for Relapsed IDH2-mutated AML
NCT03825796Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Apr 2019
- Primary completion
- Sep 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Apr 2019; status: active, not recruiting.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03825796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03825796.